Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Receivables - Accured (2019 - 2025)

Fate Therapeutics' Receivables - Accured history spans 7 years, with the latest figure at $700000.0 for Q4 2025.

  • For Q4 2025, Receivables - Accured fell 66.67% year-over-year to $700000.0; the TTM value through Dec 2025 reached $700000.0, down 66.67%, while the annual FY2025 figure was $700000.0, 66.67% down from the prior year.
  • Receivables - Accured reached $700000.0 in Q4 2025 per FATE's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $2.1 million in Q2 2021 to a low of $1000.0 in Q2 2022.
  • Average Receivables - Accured over 5 years is $1.3 million, with a median of $1.2 million recorded in 2021.
  • Peak YoY movement for Receivables - Accured: crashed 99.95% in 2022, then soared 154445.45% in 2024.
  • A 5-year view of Receivables - Accured shows it stood at $1.1 million in 2021, then dropped by 27.27% to $800000.0 in 2022, then grew by 12.5% to $900000.0 in 2023, then surged by 133.33% to $2.1 million in 2024, then crashed by 66.67% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Receivables - Accured are $700000.0 (Q4 2025), $1.4 million (Q3 2025), and $2.0 million (Q2 2025).